Drug Trial Radar · NCT00346775
Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)
Last checked: Nov 20, 2026Latest source record: Jan 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
97
Actual
Start
May 1, 2006
Primary completion
Jun 29, 2006
Study completion Jun 29, 2006
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 30, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Protocol section needs to be updated using the following text "The main goal of the study was to validate the Preference Module of the EARNS-Q and to test the reliability using Treatment Satisfaction Questionnaire for Medicines (TSQM), a validated questionnaire for determining satisfaction among different treatment. The EARNS-Q is divided into 2 modules, an Experience Module and a Preference Module. The Experience Module includes 28 items, fourteen attribute rating items followed by fourteen importance weighing questions. The Preference Module includes the same items along with preference questions related to each item as well as a global preference question.
Conditions
- Rhinitis, Allergic, Perennial
Interventions
Beclomethasone dipropionateDrug
Beclomethasone dipropionate
FlunisolideDrug
Flunisolide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Correlations of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) Preference Module With Treatment Satisfaction Questionnaire for Medicines (TSQM) Change Scores and Change in Mean Daily Reflective Total Nasal Symptom (rTNSS) ScoresTime frame: Day 1 to Day 23
- Correlation of EARNS-Q Preference Module With EARNS-Q Experience Module Change ScoresTime frame: Day 1 to Day 23
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Fresno, California
GSK Investigational Site
Napa, California
GSK Investigational Site
Roseville, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
San Jose, California
GSK Investigational Site
San Jose, California
GSK Investigational Site
Walnut Creek, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.